Evidence map›Paper›PMID 26956526›Full record

ArticleScientific reports2016

A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration.

Xin-Hua Liao, Netra Pal Meena, Noel Southall, Lunhua Liu, Manju Swaroop, Arina Li Zhang, Jan Jian Xiang, Carole A Parent, Wei Zheng, Alan R Kimmel

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Eat Prey, Live:Frontiers in immunology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Xin-Hua LiaoInstitute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China.
Netra Pal MeenaLaboratory of Cellular and Developmental Biology, National Institute of Diabetes and Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, MD 20892, USA.
Noel SouthallTherapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, The National Institutes of Health, Bethesda, MD 20892, USA.
Lunhua LiuLaboratory of Cellular and Molecular Biology, National Cancer Institute, The National Institutes of Health, Bethesda, MD 20892, USA.
Manju SwaroopTherapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, The National Institutes of Health, Bethesda, MD 20892, USA.
Arina Li ZhangInstitute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China.
Jan Jian XiangInstitute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China.
Carole A ParentLaboratory of Cellular and Molecular Biology, National Cancer Institute, The National Institutes of Health, Bethesda, MD 20892, USA.
Wei ZhengTherapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, The National Institutes of Health, Bethesda, MD 20892, USA.
Alan R KimmelLaboratory of Cellular and Developmental Biology, National Institute of Diabetes and Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USFujian Medical University · CNNational Center for Advancing Translational Sciences · US

Funding

Drug Repurposing Screening for Rare and Neglected DiseasesZIATR000018 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2015 to 2025
$24.6M
SIGNALING PATHWAYS IN CONTROL OF GROWTH AND DEVELOPMENTZIADK075040 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KIMMEL, ALAN R · 2009 to 2025
$23.9M
CHEMOTACTIC SIGNALS REGULATING HUMAN NEUTROPHIL AND BREAST METASTATIC MIGRATIONZIABC011216 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PARENT, CAROLE · 2009 to 2017
$8.6M
Signaling Events Regulating ChemotaxisZIABC010418 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PARENT, CAROLE · 2009 to 2017
$4.6M
Intramural NIH HHS
6 · The paper itself

Abstract

Chemotaxis and cell migration are fundamental, universal eukaryotic processes essential for biological functions such as embryogenesis, immunity, cell renewal, and wound healing, as well as for pathogenesis of many diseases including cancer metastasis and chronic inflammation. To identify novel chemotaxis inhibitors as probes for mechanistic studies and leads for development of new therapeutics, we developed a unique, unbiased phenotypic chemotaxis-dependent Dictyostelium aggregation assay for high-throughput screening using rapid, laser-scanning cytometry. Under defined conditions, individual Dictyostelium secrete chemoattractants, migrate, and aggregate. Chemotaxis is quantified by laser-scanning cytometry with a GFP marker expressed only in cells after chemotaxis/multi-cell aggregation. We applied the assay to screen 1,280 known compounds in a 1536-well plate format and identified two chemotaxis inhibitors. The chemotaxis inhibitory activities of both compounds were confirmed in both Dictyostelium and in human neutrophils in a directed EZ-TAXIscan chemotaxis assay. The compounds were also shown to inhibit migration of two human cancer cell lines in monolayer scratch assays. This test screen demonstrated that the miniaturized assay is extremely suited for high-throughput screening of very large libraries of small molecules to identify novel classes of chemotaxis/migratory inhibitors for drug development and research tools for targeting chemotactic pathways universal to humans and other systems.

Indexed as

Cell MovementChemotaxisCytotoxinsDictyosteliumDrug Evaluation, PreclinicalCytotoxins

Identifiers

PMID26956526
PMCPMC4783656
OpenAlexW2415830128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.